FIA
RLM

FNY Investment Advisers’s Realm Therapeutics plc American Depositary Shares RLM Stock Holding History

FNY Investment Advisers’s Portfolio RLM Stock Details RLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35,242
Closed -$138K – 1228
2019
Q1 		$138K Buy
+35,242
New +$98.9K 0.05% 221

Other funds holding RLM

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

FNY Investment Advisers's RLM Position: Q2 2019 in Review

FNY Investment Advisers sold out of Realm Therapeutics plc American Depositary Shares (RLM) in Q2 2019, closing a stake of 35,242 shares — an estimated $138K sold.

FNY Investment Advisers first reported a position in RLM in Q1 2019 and held it in 1 quarter. The position peaked at $138K in Q1 2019. 7 funds tracked by Wall St. Rank hold RLM as of Q2 2019.

  • FNY Investment Advisers reported no remaining Realm Therapeutics plc American Depositary Shares position as of Q2 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 35,242 Realm Therapeutics plc American Depositary Shares shares in Q2 2019, an estimated $138K.
  • FNY Investment Advisers first reported a position in Realm Therapeutics plc American Depositary Shares in Q1 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Realm Therapeutics plc American Depositary Shares position peaked at $138K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Realm Therapeutics plc American Depositary Shares as of Q2 2019.

Based on FNY Investment Advisers's 13F filing for Q2 2019, filed 24 Jul 2019.